| Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management VP Chavda, LK Vora, AK Pandya, VB Patravale Drug discovery today 26 (11), 2619-2636, 2021 | 180 | 2021 |
| SARS‐CoV‐2 variants and vulnerability at the global level VP Chavda, AB Patel, DD Vaghasiya Journal of medical virology 94 (7), 2986-3005, 2022 | 117 | 2022 |
| DNA vaccines for SARS-CoV-2: toward third-generation vaccination era VP Chavda, R Pandya, V Apostolopoulos Expert review of vaccines 20 (12), 1549-1560, 2021 | 100 | 2021 |
| Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review VP Chavda, J Ajabiya, D Teli, J Bojarska, V Apostolopoulos Molecules 27 (13), 4315, 2022 | 96 | 2022 |
| Nanobased nano drug delivery: a comprehensive review VP Chavda Applications of targeted nano drugs and delivery systems, 69-92, 2019 | 94 | 2019 |
| Artificial intelligence in pharmaceutical technology and drug delivery design LK Vora, AD Gholap, K Jetha, RRS Thakur, HK Solanki, VP Chavda Pharmaceutics 15 (7), 1916, 2023 | 87 | 2023 |
| Nucleic acid vaccines for COVID-19: a paradigm shift in the vaccine development arena VP Chavda, MK Hossain, J Beladiya, V Apostolopoulos Biologics 1 (3), 337-356, 2021 | 79 | 2021 |
| A global picture: therapeutic perspectives for COVID-19 VP Chavda, C Kapadia, S Soni, R Prajapati, SC Chauhan, MM Yallapu, ... Immunotherapy 14 (5), 351-371, 2022 | 78 | 2022 |
| Therapeutics for COVID-19 and post COVID-19 complications: An update D Basu, VP Chavda, AA Mehta Current Research in Pharmacology and Drug Discovery 3, 100086, 2022 | 76 | 2022 |
| COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals VP Chavda, LK Vora, DR Vihol Clinical Complementary Medicine and Pharmacology 1 (1), 100004, 2021 | 68 | 2021 |
| Nanoparticle-based delivery systems for vaccines R Bezbaruah, VP Chavda, L Nongrang, S Alom, K Deka, T Kalita, F Ali, ... Vaccines 10 (11), 1946, 2022 | 60 | 2022 |
| Global impact of delta plus variant and vaccination VP Chavda, V Apostolopoulos Expert Review of Vaccines 21 (5), 597-600, 2022 | 60 | 2022 |
| Nano-drug delivery systems entrapping natural bioactive compounds for cancer: recent progress and future challenges VP Chavda, AB Patel, KJ Mistry, SF Suthar, ZX Wu, ZS Chen, K Hou Frontiers in oncology 12, 867655, 2022 | 56 | 2022 |
| Herbal remedies, nutraceuticals, and dietary supplements for COVID-19 management: an update VP Chavda, AB Patel, D Vihol, DD Vaghasiya, KMSB Ahmed, KU Trivedi, ... Clinical Complementary Medicine and Pharmacology 2 (1), 100021, 2022 | 56 | 2022 |
| Replicating viral vector-based vaccines for COVID-19: potential avenue in vaccination arena VP Chavda, R Bezbaruah, M Athalye, PK Parikh, AS Chhipa, S Patel, ... Viruses 14 (4), 759, 2022 | 54 | 2022 |
| A veterinary vaccine for SARS-CoV-2: the first COVID-19 vaccine for animals VP Chavda, J Feehan, V Apostolopoulos Vaccines 9 (6), 631, 2021 | 54 | 2021 |
| Recent review of COVID-19 management: Diagnosis, treatment and vaccination VP Chavda, S Vuppu, T Mishra, S Kamaraj, AB Patel, N Sharma, ZS Chen Pharmacological Reports 74 (6), 1120-1148, 2022 | 53 | 2022 |
| Is booster dose strategy sufficient for omicron variant of SARS-CoV-2? VP Chavda, V Apostolopoulos Vaccines 10 (3), 367, 2022 | 52 | 2022 |
| The Delta and Omicron variants of SARS-CoV-2: what we know so far VP Chavda, R Bezbaruah, K Deka, L Nongrang, T Kalita Vaccines 10 (11), 1926, 2022 | 51 | 2022 |
| Advanced computational methodologies used in the discovery of new natural anticancer compounds VP Chavda, YN Ertas, V Walhekar, D Modh, A Doshi, N Shah, K Anand, ... Frontiers in Pharmacology 12, 702611, 2021 | 51 | 2021 |
Vasso ApostolopoulosProfessor of Immunology, Victoria University, AustraliaVerified email at vu.edu.au
